Willow Review – Flat-Rate Compounded GLP-1, With a Serious Advertising Problem

Willow, which trades at startwillow.com, is a US telehealth service selling compounded GLP-1 medication on a flat monthly price that does not rise with your dose. It offers semaglutide and tirzepatide as weekly injections and — unusually — as daily tablets, which makes it one of the few places to get a needle-free version of either drug. It is aimed at cash-pay buyers who want simple, predictable pricing. The reason we cannot recommend it more warmly is not the product but the paperwork: in December 2025 the advertising industry's self-regulatory body referred Willow to the FTC and state attorneys general over claims it could not substantiate.

Overview

The corporate entity is Willow Health Services, Inc. Note the domain carefully: the service is at startwillow.com, not willow.com, which is an unrelated business. Our earlier review linked to the wrong one, and we have fixed it — if you are searching for this company, make sure you land in the right place.

The proposition is straightforward. A free online assessment, review by a US-licensed doctor with same-day approval advertised, and compounded medication shipped free within two days. The monthly price includes the medication, the medical evaluation, unlimited access to your doctor and 24/7 support from a care team. Insurance is not required or accepted, but the company states the service is FSA and HSA eligible — worth noting, since many compounded programmes are silent on that.

To its credit, Willow now states plainly on its site that "compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA" and that they are not substitutes for Mounjaro, Zepbound, Wegovy or Ozempic. That disclosure is correct, and — as the advertising section below explains — it did not always read that way.

Willow at a Glance

How It Works, Step by Step

1. Free assessment. An online questionnaire covering health history and weight-loss goals, at no cost.
2. Doctor review. A US-licensed doctor reviews your submission; Willow advertises same-day approval.
3. Choose your format. Semaglutide or tirzepatide, weekly injection or daily tablet.
4. Payment and dispatch. You pay the monthly rate and medication is prepared by an unnamed US pharmacy partner.
5. Delivery. Free two-day discreet shipping.
6. Ongoing care. Unlimited messaging with your doctor and 24/7 care team access.

Pricing and the Real All-In Cost

Willow's site stated that treatment plans start at $299 per month when we checked on 6 August 2026, with independent coverage putting compounded semaglutide at $299 and compounded tirzepatide at $399, rising to around $549 at higher tirzepatide tiers.

The structure is genuinely clean: no membership fee, no consultation fee, free shipping, and the price does not escalate as you titrate. Flat dose pricing is a real benefit — much of the compounded market raises the price at each step up, so a rate you can budget for is worth something. Willow also says pricing is transparent with no hidden fees, and on the evidence of its own page that is fair.

Cancellation and refund terms are not published anywhere we could find, which matters more than usual here given what customers report about getting money back. Ask before you pay.

The Advertising Referral You Should Know About

This is the single most important thing on this page, and it is a matter of public record.

In fairness, there is a second half to the story, and it is better. The matter was subsequently reopened, and on 24 July 2026 Willow Health Services voluntarily discontinued the challenged advertising claims for its compounded semaglutide products. That is the outcome the process is designed to produce, and the current site's explicit "not approved or evaluated by the FDA" language is consistent with a company that has adjusted its messaging.

How much weight to give this is a judgement call, and here is ours. The claims were eventually withdrawn, which counts for something. But they were withdrawn seven months after being found unsubstantiated, and only after a referral to federal and state regulators — not at the first opportunity. The underlying issue, borrowing the evidence base of an approved drug to sell a compounded one, is precisely the thing a buyer of compounded medication most needs their supplier to be scrupulous about. It is a mark against the company's judgement, and it is why this review sits where it does.

Eligibility, Contraindications, and Side Effects

Willow does not publish BMI thresholds or other eligibility criteria, stating only that a licensed doctor reviews each patient's history and goals. Our eligibility guide covers what a thorough screen should ask.

Semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumours, based on rodent studies. You should not take these medications if you or a family member have had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious hypersensitivity reaction to the active ingredient. They are not for use in pregnancy. A history of pancreatitis, gallbladder disease, gastroparesis or other severe gastrointestinal disease, or diabetic retinopathy, warrants a specific conversation first.

Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation, abdominal pain — usually worst after a dose increase. Serious but less common risks include pancreatitis, gallbladder disease and acute kidney injury from dehydration. Choosing tablets over injections does not avoid these; the active drug is the same. See our side effects guide.

We are not quoting weight-loss percentages for Willow, and after the NAD decision that is more than an editorial preference — transposing trial results from brand-name semaglutide onto a compounded product is exactly the reasoning regulators objected to. Willow publishes no outcome data for its own patients. Treat any figure attached to this service as unverified.

Where It Is and Is Not Available

Willow does not publish a list of states it serves. The best available indication comes from its own partner programme, which lists the following as restricted states: Alabama, Alaska, Arkansas, Delaware, Kansas, Louisiana, Maine, Massachusetts, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia and Wyoming. That is 18 states, a large share of the country, and we would not describe this service as nationally available. Confirm your own state at the assessment stage before paying.

Legitimacy, Credentials, and Complaint Record

Willow is a real operating telehealth business and holds an A rating from the Better Business Bureau, which is a genuine point in its favour and sits oddly alongside the advertising referral. Its customer sentiment, however, is among the weaker records we have looked at.

On Trustpilot, Willow scores around 3.6 out of 5 — but the distribution is what to look at: roughly 49% of reviewers give one star. A near-even split between people who loved it and people who rated it as badly as possible is not a middling service, it is an inconsistent one. Trustpilot also flags that the company may use AI assistance in its replies.

The negative reports cluster around fulfilment rather than clinical care: shipping delays, orders arriving without the medication in them, and difficulty getting refunds. Positive reviews consistently praise the speed of approval and the simplicity of the pricing. Read together, that describes a company whose front end works well and whose logistics and customer recovery do not.

Willow does not name its compounding pharmacy, so you cannot check the facility's accreditation or inspection history. Given that shipping and fulfilment are where the complaints are, the anonymity of the fulfilment partner is more of a concern here than it would be elsewhere.

Where Compounded GLP-1s Stand Right Now

Willow sells compounded medication exclusively, so the regulatory position is central rather than incidental. Compounded semaglutide and tirzepatide are not FDA-approved. They are not generics — no generic version of either exists in the US — and approval of the brand-name product does not extend to a compounded preparation sharing its active ingredient. This is the exact point NAD made.

The shortages that opened this market have ended: the FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage on 21 February 2025. On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would prevent outsourcing facilities compounding them at scale; the comment period closed on 30 July 2026. Patient-specific compounding by 503A pharmacies remains lawful within narrow limits. Our compounded vs brand-name guide covers the trade-off in full.

How Willow Compares

Willow's distinguishing feature — a needle-free daily tablet — is available from TrimRx at $179, $120 a month cheaper, and from NovoCare as the FDA-approved Wegovy pill at $149. Willow is the most expensive route to the thing that makes it distinctive. That is a hard position to defend, and it is before weighing the advertising history.

Pros and Cons

Who Should Pick It, and Who Should Look Elsewhere

Willow might suit you if you specifically want compounded tirzepatide in tablet form — a combination that is genuinely hard to find — you are in a served state, and predictable flat pricing matters more to you than the absolute level. The clinical wrapper is reasonable: unlimited doctor access, 24/7 support and free fast shipping are not nothing at this price.

Look elsewhere in most other cases. If you want a tablet, TrimRx is $120/month cheaper and NovoCare sells the FDA-approved Wegovy pill for half. If you want cheap compounded medication from a provider that names its pharmacy, Cora Health and Precision Telemed both do. If you have insurance, see our insurance guide first. And if a regulator referral over unsubstantiated medical claims would bother you, it should — that is a reasonable thing to weigh.

Limitations of This Review

This review is based on Willow's published materials, BBB National Programs' published decisions, its BBB profile and Trustpilot, checked on 6 August 2026. Willow's own site publishes a starting price rather than a full price list, so the tirzepatide tiers come from independent coverage we could not verify on the site. Cancellation and refund terms are not published at all. We have not signed up, been prescribed, or received medication, so we cannot speak to shipping reliability or medication quality directly — the fulfilment problems described here are customer reports. We could not identify the compounding pharmacy or obtain an official state list. It also corrects our December 2025 review, which rated Willow 4.3 and linked to the wrong domain.

Frequently Asked Questions

Verdict

There is a decent service somewhere in here. Flat dose pricing, no hidden fees, free two-day shipping and oral formulations of both drugs is a good offer on paper, and the current site handles FDA disclosure correctly. But you can buy the same needle-free convenience for $120 a month less elsewhere, or buy an actual FDA-approved pill for half; nearly half of Trustpilot reviewers rate the experience one star, with some reporting boxes arriving empty; and the company spent seven months and a federal referral getting to a position on advertising it should have started from. Better options exist at every price point.